2024年12月6日至8日，欧洲肿瘤学会亚洲分会（ESMO Asia）年会将于新加坡召开。复宏汉霖将在本次大会上分享抗PD-1单抗H药汉斯状®、抗EGFR单抗HLX07、达雷妥尤单抗生物类似药HLX15等3款产品的最新临床研究数据。
H药为复宏汉霖自主研发的重组人源化抗PD-1单抗注射液，目前已在中国和多个东南亚国家获批上市，也是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。以临床需求为导向，公司围绕H药进行了差异化、多维度的适应症布局，覆盖肺癌、消化道肿瘤等高发大癌种。目前，H药已在中国获批4项适应症，惠及患者超过8.5万人。此外，探索H药在多项差异化适应症中疗效的创新联合疗法正在进行中，如H药联合贝伐珠单抗及化疗一线治疗转移性结直肠癌（mCRC），联合化疗用于胃癌的新辅助/辅助治疗，联合化疗同步放疗治疗局限期小细胞肺癌等。
HLX07是复宏汉霖自主研发的针对EGFR靶点的创新型生物药。基于公司成熟的抗体工程改造平台，复宏汉霖在西妥昔单抗的基础上，将HLX07的Fab区人源化，同时使该产品聚糖含量降至最低，以具备更低的免疫原性和良好的靶点亲和力。目前，公司围绕食管鳞癌、皮肤鳞癌、鼻咽癌等多个实体瘤适应症，正在积极开展HLX07单药或联合H药的II期临床探索。
HLX15是复宏汉霖自主开发的一款全人源抗CD38 IgG1κ单克隆抗体，有望用于治疗多发性骨髓瘤（Multiple myeloma，MM）。参照中国、欧盟和美国的生物类似药技术指导原则的要求，复宏汉霖采用逐步递进、比对及相似性评价原则，对HLX15与原研达雷妥尤单抗进行了头对头的药学分析和体内外药理学比对研究。2024年6月，HLX15的I期临床研究已成功完成，达到了所有预设的研究终点。
以下为此次入选ESMO Asia的详细信息：
ASTRUM-004R研究：斯鲁利单抗一线治疗局部晚期或转移性鳞状非小细胞肺癌的多中心、单臂、真实世界研究
论文题目：First-Line Serplulimab for Advanced Squamous Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Real-World ASTRUM-004R Study
摘要编号：682P
主要研究者：沈波，江苏省肿瘤医院、江苏省肿瘤研究所、南京医科大学附属肿瘤医院
展示时间：2024年12月7日 下午17:50-18:45（新加坡时间）
晚期非透明细胞肾细胞癌（nccRCC）一线治疗中，呋喹替尼联合斯鲁利单抗的疗效和安全性：单臂、多中心临床试验
场次：Mini Oral session: Genitourinary tumours
论文题目：Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial
摘要编号：274MO
报告人：黄吉玮，上海交通大学医学院附属仁济医院
演讲时间：2024年12月8日 上午9:42 – 9:47（新加坡时间）
HLX07-NPC：HLX07联合斯鲁利单抗和化疗对比安慰剂联合斯鲁利单抗和化疗作为鼻咽癌一线治疗：一项随机、双盲、多中心II期研究
场次：Mini Oral session: Head and neck cancers
论文题目：First-line HLX07 vs. Placebo Combined with Serplulimab and Chemotherapy for Nasopharyngeal Cancer: a Randomised, Double-blind, Multicentre Phase 2 study
摘要编号：LBA3
牵头主要研究者：张力，中山大学肿瘤防治中心
演讲时间：2024年12月7日 下午14:40-14:45（新加坡时间）
HLX07-CSCC：HLX07单药治疗晚期皮肤鳞状细胞癌的有效性和安全性：一项开放标签、多中心II期研究
论文题目：Efficacy and Safety of HLX07 Monotherapy in Advanced Cutaneous Squamous Cell Carcinoma: an Open-label, Multicentre Phase 2 Study
摘要编号：759P
牵头主要研究者：李常兴，南方医科大学南方医院
展示时间：2024年12月7日 下午17:50-18:45（新加坡时间）
HLX15-001：一项在男性健康受试者中比较HLX15和达雷妥尤单抗注射液的药代动力学特征、安全性、耐受性和免疫原性的I期临床研究
论文题目：A Randomised, Double-blind, Phase I Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of HLX15 and Daratumumab in Healthy Male Participants
摘要编号：63P
牵头主要研究者：苏钰文，南京医科大学附属逸夫医院
展示时间：2024年12月7日 下午17:50-18:45（新加坡时间）
关于复宏汉霖
复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已有6款产品在中国获批上市，3款产品在国际获批上市，24项适应症获批，4个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。
复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖50多个分子，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。截至目前，公司已获批上市产品包括国内首个生物类似药汉利康®（利妥昔单抗）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、汉达远®（阿达木单抗）、汉贝泰®（贝伐珠单抗）以及汉奈佳®（奈拉替尼），此外，创新产品汉斯状®（斯鲁利单抗）已获批用于治疗微卫星高度不稳定（MSI-H）实体瘤、鳞状非小细胞肺癌、广泛期小细胞肺癌和食管鳞状细胞癌，并成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。公司亦同步就16个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。
Henlius to Showcase Latest Results of 5 Clinical Trails at ESMO Asia 2024
From 6 to 8 December 2024, the European Society for Medical Oncology Asia (ESMO Asia) Congress will be held in Singapore. At this congress, Henlius will share the latest results of clinical trials of several products, including HANSIZHUANG (serplulimab), HLX07 (anti-EGFR mAb), and daratumumab biosimilar HLX15.
HANSIZHUANG (serplulimab) is a recombinant humanised anti-PD-1 monoclonal antibody（mAb）injection independently developed by Henlius, and the world's first anti-PD-1 mAb approved for the first-line treatment of SCLC. It has been approved in China and multiple countries in Southeastern Asia. Underpinned by the patient-centric strategy, Henlius has carried out a differentiated and multi-dimensional layout in the field of gastrointestinal cancer and lung cancer, covering a wide variety of indications. Up to date, HANSIZHUANG has been approved by the National Medical Products Administration (NMPA) for the treatment of 4 indications, benefiting more than 85,000 patients. Moreover, a wide variety of clinical trials on immuno-oncology combination therapies in differentiated indications has been initiated by the company to further explore the efficacy of the product, such as HANSIZHUANG plus bevacizumab and chemotherapy as first-line treatment for patients with metastatic colorectal cancer (mCRC), HANSIZHUANG plus chemotherapy as neoadjuvant/adjuvant therapy for gastric cancer (GC), and HANSIZHUANG plus chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC), etc.
HLX07 is an innovative drug targeting EGFR independently developed by Henlius. Adopting the self-developed advanced antibody engineering platform, Henlius re-engineered cetuximab by humanising its Fab regions and minimizing its glycan contents to generate HLX07 to reduce immunogenicity and maintain a high binding affinity of the product. Currently, Henlius is conducting phase 2 clinical trials to explore HLX07 as monotherapy or in combination with HANSIZHUANG (serplulimab) for the treatment of solid tumours including esophageal squamous cell carcinoma (ESCC), cutaneous squamous cell carcinoma (CSCC), and nasopharyngeal carcinoma (NPC).
HLX15 is a fully human anti-CD38 IgG1κ monoclonal antibody independently developed by Henlius. The indication to be developed for HLX15 is multiple myeloma (MM). In accordance with the biosimilar guidelines of NMPA, EMA, and FDA, HLX15 has been developed strictly following the principles of stepwise development, comparability and similarity assessment and has been compared head-to-head with reference daratumumab via analytical studies and preclinical studies. In June 2024, the phase 1 clinical trial of HLX15 met its primary endpoint.
Results to be presented at the ESMO Asia 2024 are as follows:
ASTRUM-004R Study
Title: First-Line Serplulimab for Advanced Squamous Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Real-World ASTRUM-004R Study
Presentation Number: 682P
Speaker: Bo Shen, Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital, Nanjing Medical University
Time: December 7, 2024, 17:50-18:45 PM SGT
Session: Mini Oral session: Genitourinary tumours
Title: Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial
Presentation Number: 274MO
Speaker: Jiwei Huang, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Time: December 8, 2024, 9:42 – 9:47 AM SGT
HLX07-NPC
Session: Mini Oral session: Head and neck cancers
Title: First-line HLX07 vs. Placebo Combined with Serplulimab and Chemotherapy for Nasopharyngeal Cancer: a Randomised, Double-blind, Multicentre Phase 2 study
Presentation Number: LBA3
Leading PI: Li Zhang, Sun Yat-sen University Cancer Center
Time: December 7, 2024, 14:40-14:45 PM SGT
HLX07-CSCC
Title: Efficacy and Safety of HLX07 Monotherapy in Advanced Cutaneous Squamous Cell Carcinoma: an Open-label, Multicentre Phase 2 Study
Presentation Number: 759P
Leading PI: Changxin Li, Southern Medical University Nanfang Hospital
Time: December 7, 2024, 17:50-18:45 PM SGT
HLX15-001
Title: A Randomised, Double-blind, Phase I Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of HLX15 and Daratumumab in Healthy Male Participants
Presentation Number: 63P
Leading PI: Yu-wen Su, Sir Run Run Hospital, Nanjing Medical University
Time: December 7, 2024, 17:50-18:45 PM SGT
About Henlius
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 6 products have been launched in China, 3 have been approved for marketing in overseas markets, 24 indications are approved worldwide, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.
Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab) and HANNAIJIA (neratinib), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.
联系方式
媒体：PR@Henlius.com
投资者：IR@Henlius.com
喜欢本文内容
点击下方按钮·分享 ·收藏 ·点赞 ·在看
